scispace - formally typeset
T

Tomasz Szczepański

Researcher at Medical University of Silesia

Publications -  267
Citations -  10296

Tomasz Szczepański is an academic researcher from Medical University of Silesia. The author has contributed to research in topics: Minimal residual disease & Gene rearrangement. The author has an hindex of 47, co-authored 238 publications receiving 8935 citations. Previous affiliations of Tomasz Szczepański include University of Silesia in Katowice & Wrocław Medical University.

Papers
More filters
Journal ArticleDOI

Limfocyty regulatorowe – rola fizjologiczna oraz udział w patologii wieku dziecięcego (część I)

Aleksander Matyl, +2 more
- 01 Nov 2009 - 
TL;DR: Streszczenie Limfocyty regulatorowe (Treg) stanowią heterogenną subpopulacje limfocytow, bedących istotnym ogniwem ukladu immunologicznego, jak rowniez formy komunikacji z innymi grupami komorek.
Journal ArticleDOI

Venetoclax Use in Paediatric Haemato-Oncology Centres in Poland: A 2022 Survey

Katarzyna Bobeff, +19 more
- 01 Apr 2023 - 
TL;DR: Venetoclax, the best established BH3-mimetic, is a practice-changing proapoptotic drug in blood cancers in adults as mentioned in this paper , is not incorporated into paediatric treatment schedules in Poland but it has been already used in patients that failed conventional therapy in Polish paediatric haemato-oncology departments.
Journal ArticleDOI

Rakowiak u dzieci – opis przypadku i przegląd piśmiennictwa

Tomasz Szczepański, +4 more
- 01 Feb 2007 - 
TL;DR: Przedstawiono przypadek 16-letniej dziewczynki leczonej z powodu nawracających infekcji drog oddechowych, u ktorej na podstawie badan radiologicznych, bronchoskopii i badania histopatologicznego, ustalono rozpoznanie rakowiaka
Book ChapterDOI

Analysis of Minimal Residual Disease with the Use of Rearrangements of Ig/TCR Genes Through RQ-PCR

Małgorzata Dawidowska, +4 more
TL;DR: Although this approach is laborious, it requires experienced and qualified personnel, and extensive standardization, it is applicable in more than 95 % of acute lymphoblastic leukemia patients and enables MRD assessment with high sensitivity, which makes it a valuable tool for the management of ALL treatment.

Study )rearranged acute lymphoblastic leukemia: results from the Interfant-99 MLL ( mixed-lineage-leukemia poor prognostic subgroup of infants with Improved outcome with hematopoietic stem cell transplantation in a

Ram Suppiah, +22 more